{"entity":{"id":"nct02432846","kind":"trial","name":"Intratumoral Vaccination With Intuvax Pre-nephrectomy Followed by Sunitinib Post-nephrectomy vs Sunitinib Post-nephrectomy in Newly Diagnosed Metastatic Renal Cell Carcinoma (mRCC)","aka":[],"tldr":"A phase 2 trial of Ilixadencel run by Mendus, completed.","summary":"Intratumoral Vaccination With Intuvax Pre-nephrectomy Followed by Sunitinib Post-nephrectomy vs Sunitinib Post-nephrectomy in Newly Diagnosed Metastatic Renal Cell Carcinoma (mRCC) is a phase 2 interventional study registered as NCT02432846 by Mendus, with 88 participants enrolled, started 2015-04. Conditions recorded: Renal Cell Carcinoma, Metastatic. Interventions recorded: Intuvax (INN: ilixadencel) and Sunitinib.","status":"completed","asOf":"2026-11-03","links":[{"label":"ClinicalTrials.gov NCT02432846","url":"https://clinicaltrials.gov/study/NCT02432846"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["rcc"],"sections":[],"technologies":[],"targets":[],"drugs":["ilixadencel"],"companies":["mendus"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT02432846","phase":"2","setting":"An Open-label, Randomized, Controlled, Multicenter, Phase II Study Evaluating Safety and Efficacy of Intratumorally Administered Intuvax Pre-nephrectomy Followed by Sunitinib Post-nephrectomy, Compared to Sunitinib Post-nephrectomy in Metastatic Renal Cell Carcinoma Patients","sponsor":"Mendus","enrolled":88,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct02432846/","neighbours":{"cancer":[{"id":"rcc","kind":"cancer","name":"Renal cell carcinoma","route":"/cancers/rcc/"}],"drug":[{"id":"ilixadencel","kind":"drug","name":"Ilixadencel","route":"/drugs/ilixadencel/"}],"company":[{"id":"mendus","kind":"company","name":"Mendus","route":"/companies/mendus/"}]}}